RevolutionLogo.png
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
April 29, 2020 08:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program
March 18, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
March 09, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 18, 2020 16:01 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive...
RevolutionLogo.png
Revolution Medicines Announces Pricing of Initial Public Offering
February 12, 2020 19:38 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its initial public offering of 14,000,000 shares of common stock at a...
cor.png
IDC MarketScape Positions Parallels as a Major Player in New Worldwide Virtual Client Computing Vendor Assessment
January 27, 2020 09:00 ET | Corel
BELLEVUE, Wash., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Parallels® (parallels.com), a leading innovator in virtualization that makes it simple to run Windows applications from any device, today announced...
Parallels Remote Application Server 17.1 Empowers Service Providers and Businesses to Quickly Address Market Demands and Tailor VDI Solutions for Customers
October 24, 2019 09:00 ET | Corel
BELLEVUE, Wash., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Today, Parallels® announced that it will preview version 17.1 of Parallels® Remote Application Server™ (Parallels® RAS™, parallels.com/ras)—which...
High Density, High Performance: PT Tests Dell PowerEdge M820 Blade Server
September 05, 2014 08:00 ET | Principled Technologies
DURHAM, NC--(Marketwired - September 05, 2014) - In its on-site data center, Principled Technologies (PT) compared the Oracle Database performance and RAS features of the PowerEdge M820 to those of a...
Sparx Systems and CSIRO Sign Collaboration Agreement
April 07, 2014 23:00 ET | Sparx Systems Pty Ltd
CRESWICK, AUSTRALIA--(Marketwired - April 8, 2014) - Sparx Systems and CSIRO have signed a research and development agreement that will help address global challenges in geospatial...